1356054-64-2

Upstream product

• 131774-72-6 3-hydrazino-benzenesulfonic acid amide 
• 153034-82-3 [(fluoro-2-iodo-4)pyrid-3-yl]-carboxaldehyde 

Downstream Products

• 1356053-56-9 3-(4-(4-methoxypyridin-3-yl)-1H-pyrazolo[3,4-b]pyridin-1-yl)benzenesulfonamide 
• 1356054-65-3 1-(3-sulfamoylphenyl)-1H-pyrazolo[3,4-b]pyridin-4-ylboronic acid 

Relevant academic research and scientific papers

AZAINDAZOLE COMPOUNDS

Disclosed are azaindazole compounds of Formula (I), or pharmaceutically acceptable salts thereof, wherein W is CR4 or N; and R1, R2, R3, and R4 are defined herein. Also disclosed are methods of using such compounds in the treatment of at least one CYP17 associated condition, such as, for example, cancer, and pharmaceutical compositions comprising such compounds.

SUBSTITUTED AZAINDAZOLE COMPOUNDS

Disclosed are azaindazole compounds of Formula (I): or pharmaceutically acceptable salts thereof, wherein: Q is: (i) 5-membered heteroaryl comprising at least one nitrogen heteroatom and substituted with zero to 2 Rg; or (ii) 9- to 10-membered bicyclic heteroaryl selected from Formula (II) and; wherein Ring A is a 5- to 6-membered aryl or heteroaryl fused ring substituted with zero to 2 Rg; and R1, R2, R3, and Rg are defined herein. Also disclosed are methods of using such compounds in the treatment of at least one CYP17 associated condition, such as, for example, cancer, and pharmaceutical compositions comprising such compounds.